Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a university clinic in Sweden

PharmacoEconomics

Volumn 28, Issue SUPPL. 1, 2010, Pages 49-57

  Ghatnekar, Ola ^a   Hjortsberg, Catharina ^a   Gisslén, Magnus ^b   Lindbäck, Stefan ^c   Löthgren, Mickael ^d  

^a SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c Tibotec a division of Janssen Cilag AB   (Sweden)

^d Janssen Cilag AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; LAMIVUDINE PLUS ZIDOVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; COUNSELING; DIAGNOSTIC PROCEDURE; DRUG COST; FEMALE; HEALTH CARE UTILIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; REGISTER; RETROSPECTIVE STUDY; SWEDEN;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; AMBULATORY CARE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE PROGRESSION; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HEALTH SERVICES ACCESSIBILITY; HIV; HIV INFECTIONS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; SWEDEN; UNIVERSITIES; YOUNG ADULT;

EID: 78650755091     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11587440-000000000-00000     Document Type: Article

References (16)

1. Arneborn M, Blaxhult A. Increase of reported HIV infections in Sweden. Euro Surveill 2007; 12: E070607.3
2. Socialstyrelsen [the Swedish National Board of Health and Welfare]. HIV och AIDS i vården i storstadsregionerna [In Swedish only]. Art.nr. Stockholm, Sweden: Socialstyrelsen, 1994 Mar 15.
3. Fredlund H, Giesecke J. Smittsamma sjukdomar kostar pengar. Läkartidningen [In Swedish only] 1998; 95: 522-6
4. Bozzette SA, Joyce G, Mc Caffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy.NEngl JMed 2001; 344: 817-23
5. Stoll M, Claes C, Schulte E, et al. Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART. Eur J Med Res 2002; 7: 463-71
6. Youle M, Trueman P, Simpson K. Health economics in HIV disease. A review of the European literature. Pharmaco- Economics 1999; 15 Suppl. 1: 1-12
7. FASS, Pharmaceutical Specialities in Sweden, 2006. Linfo, Stockholm, Sweden.
8. Regional Tariffs and Fees for the Southern Health Care Region, 2006 [In Swedish]. Southern Regional Health Care Committee: Lund, Sweden 2005-12-20.
9. The Swedish Council on Technology Assessment in Health Care, Chemotherapy for cancer, Yellow Report 155/2, 2001 ISBN: 91-87890-70-4.
10. Roberts RR, Kampe LM, Hammerman M, et al. The cost of care for patients with HIV from the provider economic perspective. AIDS Patient Care STDs 2006; 20 (12): 876-86
11. Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4 < 200 cells/mL) with HIV infection. HIV Med 2004; 5: 93-8
12. Druyts EF, Yip B, Lima VD, et al. Health care services utilization stratified by virological and immunological markers of HIV: Evidence from a universal health care setting. HIV Med 2009; 10: 88-93
13. Liu GG, Guo JJ, Smith SR. Economic costs to business of the HIV/AIDS epidemic. PharmacoEconomics 2004; 22: 1181-94
14. Oliva J, Roa C, del Llano J. Indirect costs in ambulatory patients with HIV/AIDS in Spain: A pilot study. Pharmaco- Economics 2003; 21: 1113-21
15. Josephson F, Albert J, Flamholc L, et al. Antiretroviral treatment of HIV infection: Swedish recommendations 2007. Scand J Infect Dis 2007; 39: 486-507
16. GisslénM, Albert J, Ahlqvist-Rastad J, et al. Antiretroviral treatment of HIV infection: Swedish recommendations 2005. Scand J Infect Dis 2006; 38: 86-103